#1 Clinical Trials Search in Europe

Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide

This article explores the ongoing clinical trials of DYNE-101, a novel drug developed by Dyne Therapeutics, Inc. for the treatment of Myotonic Dystrophy Type 1 (DM1). DYNE-101 is a humanized IgG1 kappa fragment antibody targeting TFR1 conjugated to P125 oligonucleotide, administered through intravenous injection or infusion. The trials aim to assess the safety, tolerability, and effectiveness of this innovative treatment for patients with DM1, a genetic disorder affecting muscle function and other body systems.

Table of Contents

What is DYNE-101?

DYNE-101 is an innovative medication being developed to treat Myotonic Dystrophy Type 1 (DM1). It is classified as a biological/biotechnological product and is administered through intravenous injection or infusion.[1]

The active substance in DYNE-101 is a humanised IgG1 kappa fragment antibody targeting TFR1 conjugated to P125 oligonucleotide. This complex name describes a specially designed antibody that targets a specific protein in the body (TFR1) and is linked to a small piece of genetic material (oligonucleotide).[1]

Target Condition: Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1 (DM1) is a genetic disorder that affects multiple body systems. It is characterized by muscle weakness, difficulty relaxing muscles (myotonia), and various other symptoms affecting the heart, eyes, and other organs.[1]

How DYNE-101 Works

While the exact mechanism is not fully described in the provided information, DYNE-101 is designed to target the underlying cause of DM1. The medication aims to affect the splicing index and DMPK RNA expression in muscle tissue, which are key factors in the development of DM1 symptoms.[1]

Clinical Trial Overview

DYNE-101 is currently being studied in a Phase 1/2 clinical trial. This trial is designed to evaluate the safety, tolerability, and effectiveness of the medication in patients with Myotonic Dystrophy Type 1.[1]

The study involves multiple doses of DYNE-101 administered intravenously to participants. Researchers will be closely monitoring various aspects of the participants’ health and muscle function throughout the trial.[1]

Eligibility Criteria

The study has specific criteria for who can participate. Some key inclusion criteria are:

  • Age 18 to 50 years
  • Confirmed diagnosis of DM1 with specific genetic characteristics
  • Onset of DM1 muscle symptoms at age 12 or older
  • Visible muscle stiffness (myotonia)
  • Certain levels of hand grip and ankle strength
  • Ability to perform specific physical tests without assistive devices

There are also several exclusion criteria, such as certain medical conditions or use of specific medications, to ensure participant safety and study accuracy.[1]

Study Objectives

The main goals of this clinical trial are:

  1. To assess the safety and tolerability of DYNE-101
  2. To evaluate how DYNE-101 affects muscle tissue
  3. To measure changes in muscle function after treatment
  4. To understand how the drug moves through the body (pharmacokinetics)
  5. To check if the body produces antibodies against the drug

Researchers will use various tests and measurements to evaluate these objectives, including muscle biopsies, strength tests, and blood analyses.[1]

Potential Benefits

While it’s important to note that the effectiveness of DYNE-101 is still being studied, the researchers hope to see improvements in several areas:

  • Reduced muscle stiffness (myotonia)
  • Increased muscle strength
  • Improved performance in physical tasks (walking, climbing stairs, etc.)
  • Changes in genetic markers associated with DM1

These potential benefits could significantly improve the quality of life for people with Myotonic Dystrophy Type 1.[1]

Safety Considerations

As with any clinical trial, participant safety is a top priority. The study includes careful monitoring for any side effects or adverse events. Some specific safety measures include:

  • Regular check-ups and medical tests
  • Monitoring of heart function
  • Screening for potential allergic reactions
  • Evaluation of liver and kidney function

It’s important to note that as DYNE-101 is still in the testing phase, not all potential risks may be known. Participants in the trial will be closely monitored and informed of any new safety information that becomes available.[1]

Aspect Details
Drug Name DYNE-101
Drug Type Humanised IgG1 kappa fragment antibody targeting TFR1 conjugated to P125 oligonucleotide
Condition Treated Myotonic Dystrophy Type 1 (DM1)
Administration Route Intravenous injection/infusion
Trial Phase Phase 1/2
Primary Objective Evaluate safety and tolerability of multiple IV doses
Key Secondary Objectives Assess effects on muscle tissue, changes in muscle parameters, pharmacokinetics, immunogenicity
Main Inclusion Criteria Adults 18-50 years, confirmed DM1 diagnosis, specific muscle strength criteria
Key Assessments Muscle biopsies, grip strength, walking tests, stair tests, blood tests
Primary Endpoint Incidence of treatment-emergent adverse events
Manufacturer Dyne Therapeutics, Inc.

FAQ

  • What is DYNE-101 and how does it work? DYNE-101 is a biological drug designed to treat Myotonic Dystrophy Type 1. It's a humanized antibody fragment that targets a specific protein (TFR1) and is linked to a special genetic material (P125 oligonucleotide). This combination is intended to address the underlying cause of DM1 at the genetic level.
  • Who is eligible to participate in the DYNE-101 clinical trials? Eligible participants are adults aged 18 to 50 with a confirmed diagnosis of DM1, specific muscle strength criteria, and the ability to complete certain physical tests. They must not have certain medical conditions or be taking medications that could interfere with the study results.
  • What are the main objectives of the DYNE-101 clinical trials? The primary objective is to evaluate the safety and tolerability of multiple intravenous doses of DYNE-101 in DM1 patients. Secondary objectives include assessing its effects on muscle tissue, changes in muscle parameters, how the drug moves through the body, and the body's immune response to the drug.
  • What kind of tests and assessments will participants undergo during the trial? Participants will undergo various tests including muscle biopsies, hand grip strength measurements, walking tests, stair climbing tests, and blood tests. They will also be monitored for any side effects or adverse reactions to the drug.
  • How long will the clinical trials for DYNE-101 last? The exact duration of the trials is not specified in the provided information. However, clinical trials typically last several months to a few years, depending on the phase of the study and the specific research goals.

Ongoing Clinical Trials on Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide

  • A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Italy The Netherlands +1

  • Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

    Not recruiting

    2 1
    Investigated drugs:
    France Germany Italy The Netherlands

Glossary

  • Myotonic Dystrophy Type 1 (DM1): A genetic disorder that affects muscle function, causing muscle weakness and difficulty relaxing muscles (myotonia). It can also affect other body systems.
  • DYNE-101: An investigational drug developed to treat Myotonic Dystrophy Type 1, consisting of a humanized antibody fragment targeting TFR1 conjugated to a P125 oligonucleotide.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes significant disability, or leads to birth defects.
  • Splicing Index: A measure of how genes are processed (spliced) to create functional proteins, which is often affected in DM1.
  • DMPK RNA: The genetic material produced from the DMPK gene, which is affected in Myotonic Dystrophy Type 1.
  • Dynamometer: A device used to measure muscle strength, particularly grip strength in this study.
  • vHOT: Likely refers to a test used to measure myotonia (difficulty relaxing muscles) in patients with DM1.
  • Quantitative Myometry Testing (QMT): A method to objectively measure muscle strength using specialized equipment.
  • Antidrug Antibodies (ADAs): Antibodies produced by the immune system in response to a therapeutic drug, which can affect the drug's effectiveness or safety.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dyne-101-for-patients-with-myotonic-dystrophy-type-1/